Cargando…
Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma
PURPOSE: The aim of this study was to assess signs and symptoms of ocular surface disease (OSD) and the cytomorphological changes of ocular surface in glaucoma patients using preserved antiglaucoma drops. METHODS: In this cross-sectional study, 109 participants (79 patients with topical medication a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399518/ https://www.ncbi.nlm.nih.gov/pubmed/25914521 http://dx.doi.org/10.2147/OPTH.S81247 |
_version_ | 1782366939429994496 |
---|---|
author | Cvenkel, Barbara Štunf, Špela Srebotnik Kirbiš, Irena Strojan Fležar, Margareta |
author_facet | Cvenkel, Barbara Štunf, Špela Srebotnik Kirbiš, Irena Strojan Fležar, Margareta |
author_sort | Cvenkel, Barbara |
collection | PubMed |
description | PURPOSE: The aim of this study was to assess signs and symptoms of ocular surface disease (OSD) and the cytomorphological changes of ocular surface in glaucoma patients using preserved antiglaucoma drops. METHODS: In this cross-sectional study, 109 participants (79 patients with topical medication and 30 untreated controls) completed the Ocular Surface Diseases Index (OSDI) questionnaire and underwent an ophthalmic examination, including Schirmer test, tear film breakup time (TBUT), and fluorescein staining. Conjunctival specimens were collected by impression cytology and analyzed by light microscopy using Nelson’s grading scheme (grades 0–3). This classification is based on the nucleus-to-cytoplasm ratios of epithelial cells and the numbers of goblet cells, with grade 2 considered abnormal. RESULTS: The medication group had significantly shorter TBUT (median [interquartile range]: 6.0 seconds [5.0–8.0 seconds] vs 9.5 seconds [6.0–12.3 seconds]; P<0.03), greater fluorescein staining (1.0 [0.75–1.25] vs 0 [0–0.25]; P<0.001), and higher impression cytology grade than the control group (median [range]: 1.0 [1:2 to 1:6] vs 0.6 [1:2 to 1:4]; P<0.001). The increasing number of drops instilled per day was associated with an increase in fluorescein staining (Spearman’s rho r=0.475; P<0.001) and shorter TBUT (r=−0.278; P=0.014). The OSDI did not discriminate between the two groups. CONCLUSION: Clinical tests and impression cytology showed ocular surface damage in patients using preserved antiglaucoma medications. However, there was no statistically and clinically significant difference in symptoms measured by OSDI score between the medication and control groups. |
format | Online Article Text |
id | pubmed-4399518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-43995182015-04-24 Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma Cvenkel, Barbara Štunf, Špela Srebotnik Kirbiš, Irena Strojan Fležar, Margareta Clin Ophthalmol Original Research PURPOSE: The aim of this study was to assess signs and symptoms of ocular surface disease (OSD) and the cytomorphological changes of ocular surface in glaucoma patients using preserved antiglaucoma drops. METHODS: In this cross-sectional study, 109 participants (79 patients with topical medication and 30 untreated controls) completed the Ocular Surface Diseases Index (OSDI) questionnaire and underwent an ophthalmic examination, including Schirmer test, tear film breakup time (TBUT), and fluorescein staining. Conjunctival specimens were collected by impression cytology and analyzed by light microscopy using Nelson’s grading scheme (grades 0–3). This classification is based on the nucleus-to-cytoplasm ratios of epithelial cells and the numbers of goblet cells, with grade 2 considered abnormal. RESULTS: The medication group had significantly shorter TBUT (median [interquartile range]: 6.0 seconds [5.0–8.0 seconds] vs 9.5 seconds [6.0–12.3 seconds]; P<0.03), greater fluorescein staining (1.0 [0.75–1.25] vs 0 [0–0.25]; P<0.001), and higher impression cytology grade than the control group (median [range]: 1.0 [1:2 to 1:6] vs 0.6 [1:2 to 1:4]; P<0.001). The increasing number of drops instilled per day was associated with an increase in fluorescein staining (Spearman’s rho r=0.475; P<0.001) and shorter TBUT (r=−0.278; P=0.014). The OSDI did not discriminate between the two groups. CONCLUSION: Clinical tests and impression cytology showed ocular surface damage in patients using preserved antiglaucoma medications. However, there was no statistically and clinically significant difference in symptoms measured by OSDI score between the medication and control groups. Dove Medical Press 2015-04-08 /pmc/articles/PMC4399518/ /pubmed/25914521 http://dx.doi.org/10.2147/OPTH.S81247 Text en © 2015 Cvenkel et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Cvenkel, Barbara Štunf, Špela Srebotnik Kirbiš, Irena Strojan Fležar, Margareta Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title_full | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title_fullStr | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title_full_unstemmed | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title_short | Symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
title_sort | symptoms and signs of ocular surface disease related to topical medication in patients with glaucoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399518/ https://www.ncbi.nlm.nih.gov/pubmed/25914521 http://dx.doi.org/10.2147/OPTH.S81247 |
work_keys_str_mv | AT cvenkelbarbara symptomsandsignsofocularsurfacediseaserelatedtotopicalmedicationinpatientswithglaucoma AT stunfspela symptomsandsignsofocularsurfacediseaserelatedtotopicalmedicationinpatientswithglaucoma AT srebotnikkirbisirena symptomsandsignsofocularsurfacediseaserelatedtotopicalmedicationinpatientswithglaucoma AT strojanflezarmargareta symptomsandsignsofocularsurfacediseaserelatedtotopicalmedicationinpatientswithglaucoma |